Butoxamine hydrochloride Property

form 

Solid

color 

White to off-white

Safety

Hazard Codes 

Xn

Risk Statements 

22-36

Safety Statements 

26

WGK Germany 

3

Hazard and Precautionary Statements (GHS)

Symbol(GHS)

Signal word

Warning

Hazard statements

H302Harmful if swallowed

H319Causes serious eye irritation

Precautionary statements

P264Wash hands thoroughly after handling.

P264Wash skin thouroughly after handling.

P270Do not eat, drink or smoke when using this product.

P280Wear protective gloves/protective clothing/eye protection/face protection.

P301+P312IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

P337+P313IF eye irritation persists: Get medical advice/attention.

Butoxamine hydrochloride Chemical Properties,Usage,Production

Originator

Butoxamine,SigmaAldrich

Uses

Antidiabetic; antihyperlipoproteinemic.

Uses

Butoxamine Hydrochloride is a beta-2 selective beta blocker. β2-adrenergic receptor(AR) antagonist; Antiarrhythmic;

Manufacturing Process

548.0 g (2 mol) of 2,5-dimethoxy-α-bromopropiophenone was dissolved in 500 ml of acetanitrile and 365.0 g (5 mol) of t-butylamine was added. The solution was allowed to stand at room temperature for 64 h and was then diluted with 2 L of anhydrous ether. The precipitated t-butylamine hydrobromide was filtered off and washed with ether. The filtrate and washings were concentrated in vacuo using a water-bath kept at 40°C. When most of the solvent had been removed, the residual material was dissolve in cold methanol and acidified with hydrochloric acid. The solution was then taken down to dryness in vacuo on the steam bath and the 1-(2,5- dimethoxyphenyl)-2-(t-butylamino)propiophenone was obtained, melting point 175-176°C (recrystallised from an ethanol ether mixture).
The bulk of the 1-(2,5-dimethoxyphenyl)-2-(t-butylamino)propiophenone was dissolved in methanol and hydrogenated over platinum (Adams' catalyst). After removal of the catalyst, the solvent was removed in vacuo and the residual solid was dissolved in water and the solution was washed with ether.
The aqueous layer was basified (dilute sodium hydroxide solution) and the base was taken into ether. After drying over anhydrous potassium carbonate, the ether was evaporated and the base was distille at 0.3 mm pressure. So the DL-erythro 1-(2,5-dimethoxyphenyl)-2-(t-butylamino)propanol, boiling point 127-128°C was obtained.

Therapeutic Function

Oral hypoglycemic, Antihyperlipidemic